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INTRODUCTION 
Aminogl ycosides are often used to treat severe gram negative infections. It is 
desirable to achieve adequate peak concentrations for successful eradication of the infection, 
while minimizing the trough concentration, in order to decrease the amount of drug 
presented to the renal proximal tubule arid thus theoretically decrease the risk of 
nephrotoxicity. For these reasons, serum aminoglycoside concentrations are monitored. 
Cystic fibrosis (CF) patients are frequently hospitalized for treatment of 
pse udo mo rial p ul mo na r y i nfecti o ns. A n a mi nogl ycosi de i s us ual 1 y co m bi ned vi t h a n 
extended-3pectrum penicillin to treat the infection. High peak serum aminoglycoside 
concentrations are generally desired, with 8 mq/1 (for tobramycin and gentamicin) being 
necessary to effectively treat gram negative pulmonary infections.; -2 In addition, there is 
some evidence that maintaining peak serum tobramycin concentrations (STC's) between 8 
and 12 mg/1 results in at least temporary eradication of Pseudoroonas aeruginosa from 
sputum of CF patients. - In order to keep STC's greater than the minimum inhibitory 
concentration of the organism in CF for most of the dosing interval, there is evidence that 
peak concentrations as high 83 10 to 12 mg/1 are necessary.4 High peak STC's are probabl y 
necessary in CF patients because of their enhanced elimination of aminoglycosides. 
CF patients have been shown to have altered pharmacokinetic character!sites in 
handling gentamicin,5'- tobramycin,6'' and amikacin.3'5 More specifically, they generally 
have an increased volume of distribution (Yd) and an increased total body clearance. The 
mechanism responsible for these altered pharmacokinetic characteristics is not clear. A 
complication is the fact that Vd has not consistently been shown to be elevated,10 and Kelly 
et. al. reported a vide inter and intra patient variability of Vd in the CF population. 
MacDonald et. al. studied CF patients who were not in pulmonary exacerbation and found no 
increase in Vd above that of the non-CF population'2, nor did Finkelsteinand Hall3 Also, 
there is vide interpatient variability in the dose required to produce the desired serum 
concentrations, ranging from 7.5 to 26 mg/kg/day for tobramycin6' and 6.9 to 15.0 
mg/kg/day for gentamicin.6 The need for high aminoglycoside concentrations, the altered 
pharmacokinetics, 8nd the vide interpatient variability, make monitoring of serum 
a mi nogl ycosi de co nee nt r ati o ns a n i m po rta nt co m po ne nt of t he ma nage me nt of C F. 
One widely used method of dosing aminoglycosides is that proposed by Savchuk and 
.Zaske. 4 This method has been studied in CF patients and has been reported to be 
"adequate"-' ' and to have "worked vei l " b in its ability to predict serum aminoglycoside 
concentrations, although it has not been compared to other methods in this population. 
Bauer et. al. found that projected peak and trough aminoglycoside concentrations were not 
statistically significantly different than actual measurements.6 Kelly et. al. reported that 
85% of the measured peak concentrations fell vithin 1.4 mg/1 of the predicted value. The 
predictive error of the Sawchuk-Zaske (S2) method h8s not been previously reported in CF 
patients. 
Another method of dosing aminoglycosides can be termed simplified pharmacokinetics 
(SP). This method uses simple algebraic principles in adjusting the dose of aminoglycoside 
to achieve the desired serum concentrations. The SP method is often used clinically, but has 
net been subjected to structured clinical evaluation. 
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The purpose of this study was to compare the predictive utility of the SZ method tc 
that of the much simpler method of dosing aminoglycosides, the SP method. The SZ method 
differs in that it takes into account elimination of drug during infusion time in calculating Yd 
and the serum concentration at the end of an infusion. Many clinicians do not use programs 
or equations that take into account infusion time in their normal course of determining 
aminoglycoside dosage regimens. Thus, ve compared the two methods to see if they were 
sufficiently different in their predictive utility to recommend the use of one instead of the 
other in CF patients. The SP method would be preferable to the SZ method if it is as good a 
predictor of STC's in CF as is the SZ method (or perhaps superior), because it can easily be 
explained to clinicians and allows for a rapid and simple method of dosing aminoglycosides in 
CF. 
CF patients tend to have short elimination half-lives (tj The SP method is 
applicable only when trough concentrations are sufficiently low so that the dose may be 
increased without having to lengthen the dosing interval ( t ) . Patient3 with short t ^ s 
have low trough STC's because of their rapid elimination. Thus, CF patients are a good group 
in which to examine the SP method, in addition, if it is important to take into account 
infusion time, it is more likely to manifest itself in a population with short t ^  
whom an overestimate in prediction cf the peak serum concentration is likely if 
elimination during infusion is ignored. 
The primary objective of this study was to determine whether there was a difference 
in the predictive utility of the two methods in CF patients. A secondary objective was to 
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determine if either method more frequently resulted in predicted or actual trough STC's of 
greater than 2.0 mg/1. 
METHODS 
Sixteen patients were consecutively enrolled as subjects in the study from the group 
of CF patients who were admitted to the University Hospital between Jul y, 1984 and 
February, 1985 for treatment of pulmonary exacerbation. Patients of any age, without 
evidence of renal dysfunction (serum creatinine greater than 1.2 mg/dl), were accepted. 
Patients who had had blood drawn for STC determination within the last month were 
excluded. 
The initial dose of tobramycin was determined by house officer preference. Upon 
admission, patients were randomized, with the use of a random numbers table, to be dosed 
with either the SZ or the SP method. One of the i nvestigators contacted the house officer 
and ensured that orders were written for peak arid trough STC's between the first 24-48 
hours of treatment, at which time steady-state serum concentrations should have been 
reached. Selection of the exact timing of blood sampling STC's was based on ttie need to keep 
venipunctures during the daytime hours (to avoid awakening patients). Blood samples for 
determination of peak concentrations were drawn 30 minutes after the infusion of the n t h 
(third to sixth) dose; trough concentrations were drawn immediately prior to the nTn + 1 
dose. Blood for both STC's was obtained within the same dos'ng interval in order to ensure 
greater reliability in determination of elimination rate constant (ke^). The exact time of 
the start and end of the tobramycin infusion and times of venipuncture were recorded on a 
form developed for this study and kept on the patient's bedside chart. 
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The blood samples were transported to the laboratory on ice, centrifuged., and the 
serum was either assayed immediately or frozen and assayed within 48 hours. Assays were 
performed with theTDxR system ( Abbott Laboratories; Chicago, 111.), a fluorescence 
polarization immunoassay with a lower limit of sensitivity 8t our institution of 0.2 mg/1 
(95^ confidence). The coefficient of variation (+.standard deviation) between batches 
was 3.58 + 0.035% at 1.0 mg/1 and 3.37 j_0.258% at 8.0 mg/1. 1 5 The coefficient of 
variation within batches was 3.11 +_ 0.03& at 1.0 mg/1 and 2.88 +_ 0.221 % at 8.0 mg/1. 
Both dosing methods were used to obtain a desired peak serum concentration of 8.0 
mg/1, at exactly 30 minutes after the end of the infusion. Acceptable trough concentrations 
were less than 2.0 mg/1, since there is evidence to suggest an increased incidence of 
nephrotoxicity in patients with trough concentrations greater than 2.0 mg/1.1 • : 
The SZ program designed for use with Ti-59 calculators, available from St. 
Paul-Ramsey Medical Center in St. Paul, MN, was used to calculate pharmacokinetic 
parameters. The program is based on equations which assume first-order elimination of 
drug in a one-compartment open model. The operative equations for this method have been 
published and are presented below. ' 4 Although optimal use of the SZ method involves 
obtaining a pre-dose and three post-infusion concentrations, only two post-infusion STC's 
were determined in keeping with the normal practice at our institution. A third post-
infusion concentration would have theoretically added more reliability in calculation of ke| 
(elimination rate constant). A pre-dose trough would have resulted in more accuracy in 
calculation of Vd, because it would have represented the true pre-infusion concentration (Cp 
mi ni mum), which is used i n calculation of Vd. I nstead, we assumed that the trough obtai ned 
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after a dose was equal to the trough obtained before a dose, because steady state conditions 
were assumed. Based on 3erum concentration versus time data, the program is used to 
calculate kei and t 1 / 2 using the equation: 
Cp post = Cp maxe"^Kt-t'j ( i ) 
where Cp post is the serum concentration at some time during the post infusion phase, Cp 
max is the serum concentration at the end of the infusion, t is the time corresponding to Cp 
post, and f is the duration of the infusion. Vd is calculated using t" and the zero order 
infusion rate (k0): 
Vrt = kn M - e - ^ ' f ) (2) 
ke] (Cp m a x - C p 0 e - k e l t ) 
where Cp0 is the concentration in serum remaining from a previously administered dose (Cp 
minimum). Based on the above calculated parameters, the desired Cp min^ (the steady 
state Cp0) and Cp max^ (the steady state Cp max), the dosing interval, X , can be 
calculated: 




X  is rounded to give 8 practical dosing interval. The following two equations are used to 
calculate the infusion rate necessary to achieve the desired Cp max^ and the actual 
Cp min^ to expect based on the rounded X. 
fc0 = ke l Vd Cp max^ (1 - e ' k e ] t ) (4) 
( 1 .g-kelf) 
Cpmin = k 0 ( e k e l t ' - 1 ) 
ke l Vd (e*e ,*-1) 
(5) 
Calculations for the SP method are aa follows. Elimination occuring during the 
infusion was assumed to be relatively constant for each administration. Steady state 
conditions were assumed, because all concentrations were drawn after the patient had been 
on the same dosage regimen for at least 24 hours. This i8 much greater than four times 
the mean half life for tobramycin in CF patients, which has been reported to be 1.27and 
1.73 hours1 Because of this short t j ^ ^ V 8 S P 8 ^ it would be possi ble to 
achieve adequate peak concentrations, while maintaining predicted trough concentrations 
less than 2.0 mg/1, without having to lengthen x. Thus, in the following equation, (at 
steady state), kd,Vd, and f may all be considered to be constant for each patient: 
CpmaXco = D (6) 
Yd(1 -e"*®1* ) 
and 
Cpmin^ = Cpmax00e"ke1t : (7) 
where D = dose. These relationships suggest that serum concentrations, at any given 
time, are directly proportional to dose. Thus, given a certain measured Cpmax^, 
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the ratio of 8.0 mg/1 to Cpmax^ was computed. This ratio was multiplied bg the initial 
dose, yielding the dose required to produce peak concentrations of 8.0 mcg/ml at the 
initial X.  This same ratio was multiplied by the initial measured trough concent rati on 
(Cpmin^) to calculate the predicted trough. Calculations for ke1 and Vd were made using 
the following formulae: 
ke l = InCp maXoo - InCp min^ (8) 
tpeak " trough 
Vd = Dose (9) 
Cpmax^U - e ~ k e l t ) 
One method or the other was used to determine do38ge recommendations (depending 
on randomization schedule). Calculations for the concentrations each method would 
predict (given the dose that was actually used), were made for both methods. The 
predictive utility of each method was thus calculated based on the same set of STC data. 
Data were tabulated and analyzed for statistical and clinical significance as follows. 
In order to determine the predictive utility of the two methods, the mean prediction error 
(ME) and mean squared prediction error (MSE) were calculated as de8cribed by Sheiner 
and Beal.19 Ninety-five percent confidence intervals (CI's) were calculated for the 
differences between the two MSE's (& MSE) and the two ME's (&ME). Our chosen level of 
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significance vas 0.05. If the CI for a MSE includes zero, then there is no statistically 
significant difference in the precision of the two methods. If the CI does not include zero, 
the method with the smaller MSE is considered more precise. If the CI for &ME includes 
zero, then there Is no difference in the bias or the tvo methods, we considered a ame or 
greater than 1.0 mg/1 to represent a clinically significant difference. 
The second objective V8S to determine if the tvo methods differed in the frequency 
of producing trough concentrations greater than 2.0 mg/1. This frequency vas  calculated 
for both methods, and analyzed descriptively by calculating the percentage of patients vith 
elevated troughs at the second set of serum concentrations. A difference betveen the tvo 
methods in the frequency of trough concentrations greater than 2.0 mg/1 would need to be 
weighed, along vith any differences in predictive utility, to decide vhich, if either, of the 




Data vere collected from July 1,1984 to February 1, 1985. Sixteen patients 
successfully completed tvo sets of peak snd trough determinations. Subjects ranged in age 
from 1 to 30 years (median 19 years). Ten vere female and six vere male. All had 
serum creatinine concentrations less than 1.2 mg/dl (mean 0.8 mg/dl). All subjects 
vere treated vith standard medications used in CF including pancreatic enzymes, an 
antipseudomonal penicillin, and frequently theophylline and vltamins E and K. 
The predicted and measured tobramycin concentrations are shovn in Figures 1-4. 
The values for predictive error (PE, the predicted tobramycin serum concentration minus 
the measured concentration) for peaks and troughs, calculated for both the SZ and SP 
methods, are reported in Tables 1 and 2. All peak STC's (predicted and measured) are 
extrapolated to the concentration achieved at thirty minutes after the end of the infusion. 
All trough concentrations (predicted and measured) are extrapolated to one minute prior 
to the next dose. 
The difference in the mean squared error (aMSE) of the methods vas 0.49 for 
peaks and 0.04for troughs. The 95% confidence interval (CI) for peaks vas -0.68 to 
1.42 and the 95% CI for troughs V83 -0.04to 0.12. BothCI's included zero, indicating 
that there vas no statistically significant difference in the capacity of the tvo methods to 
accurately predict serum concentrations. 
The difference in the mean error betveen the tvo methods UME) vas equal to 0.12 
mg/1 for peaks and -0.06 mg/1 for troughs. The 95% CI for peaks vas -0.02 to 0.26 and 
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for troughs W83 -0.14to 0.02 mg/1. Since both Cl's included zero, there was no 
statistically significant difference between the two methods in their mean bias in 
predicting STC's. 
The £ error i n this study was 18%, based on the standard deviation (S.D.) i n 
predictive error that we obtained ( + 4.6 mg/1). Thus, there is an 18% chance that there 
was a difference between the two methods that we failed to detect. Based on the previously 
published S.D. of differences in predicted versus measured STC's for the SZ method (1.4 
mg/1),20,21 the predicted £ error for this study wa3 expected to be 4.8%. 
It should be noted that although the two methods were quite similar in their degree 
of predictive utility and the mean bias was small (less that 1.0 mg/1), neither method was 
very reliable in predicting STC's for any given patient. Thus, although the ME for peaks is 
only -1.01 mg/1 (SZ) and -1.13 mg/1 (SP),the range was from -10.0 to 4.7 mg/1 (SZ) 
and from -9.7 to 4.8 mg/1 (SP). The S.D. was 4.64 mg/1 (SZ) and 4.60 mg/1 (SP). For 
troughs, the range for PE was from -1.0 to 1.0 mg/1 (SZ) (S.D. 0.50) and from - 0.8 to 
0.8 mg/1 (SP) (S.D. 0.45). 
Neither method resulted in predicted or measured troughs greater than 2.0 mg/1. 
We calculated Yd and k^ based on STC's obtai ned one to two days after admission and 
again three to four days after admission. The results are listed in Tables 3 and 4. There 
is large variability in the Yd calculated for patients with both methods. The mean Yd 
decreased from 0.5391 /kg to 0.3911 /kg (SZ) and from 0.6641 /kg to 0.5061 /kg (SP). 




The CF patients involved in this study routinely have peak and trough STC's 
measured to aid i n determi ni ng thei r dose of tobramyci n. Usual! y, peak and trough 
concentrations are obtained the day after admission, dosage is altered (either by housestaff 
or pharmacy residents or staff) according to the SP method, and frequently, no further 
STC's are drawn for that admission. The SZ method has been used to aid i n dosi ng of 
aminoglycosides in CF. 4 - 7 To date, the SZ method has not been compared to the SP method 
to determine if there is a difference in their predictive utility. Because the SP method 
requires no detailed calculations, it can be used easily and quickly by housestaff or 
pharmacy staff to make dosage changes. We found no statistically significant difference 
between the two methods. Thus, there appears to be no advantage to using calculator or 
computer programs using the SZ method to aid in making dosage changes in CF patients 
with normal renal function. 
However, the use of the SP method vas not as simple as it first appeared. The major 
reason for this is that the SP method requires that the peak concentration be reflective of 
the thirty minute post-infusion peak and that the trough concentration be reflective of the 
one minute pre-infusion trough. In actuality, peaks and troughs we re infrequently drawn 
at exactly these times. Thus, almost all measured peaks and troughs had to be extrapolated 
to the true peaks (thirty minute post-infusion) 8nd troughs (one minute per-infusion), a 
procedure which is si mple enough for the cli nician with skills i n pharmacoki netics, but 
which is generally foreign to the house officer. Thus, even the recommendations based 
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upon the SP method required interpretation by a clinical pharmacist and vere not readily 
apparent to the housestaff. Nonetheless, such calculations are more easily done than those 
required by the SZ method, and can be quickly performed in the patient care areas without 
having to use programmable calculators or computer programs. 
The effects of a peak STC being drawn late were sometimes remarkable. In one 
i nstance, the measured peak was drawn approxi matel y one- half hour late and was 8.3 
mg/1. When it was extrapolated back to a thirty minute post-infusion peak, the value was 
10.4 mg/1. In this case, the house officer would probably have been satisfied with a peak 
of 8.3 mg/1 and would not have changed the dose. When it was pointed out that the "true" 
peak was 10.4 mg/1, we made recommendations to decrease the dose. The house officer did 
so, in a case where he would not have, if it were not for clinical pharmacy intervention. 
The effect of clinical pharmacy interpretation in these types of cases had impact on the 
dosage adj ustments that were made. 
DeVito and Cross address the problem of trough aminoglycoside concentrations being 
drawn one- half hour late, thus alteri ng the ti mi ng of the next dose and subsequent 
measured peak concentration.15 In patients with at of only one hour, they reported a 
13.6% increase in the calculated kej and a 2.4% decrease in the calculated Vd, with almost 
a 1.0 mg/1 error in measured Cp max. Their data, and the results obtained in this 3tudy, 
illustrate the impact that even minor errors in timing of blood draws in relationship to 
dose can have on calculated pharmacokinetic parameters and thus on the dosage changes 
made. Realistically, one cannot guarantee that the timing of dosing and blood draws will 
always be as scheduled; thus, pharmacokinetic interpretation of the results is frequently 
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necessary. 
The terror is this study vas 18%. This is less than the arbitrarily acceptable 
error of 20%. Hovever, ve had anticipated that the £ error vould be even less than 18% 
because ve did not expect that there vould be such vide variability in the predicitve 
utility of the tvo methods. 
All predicted and measured troughs vere less than 2.0 mg/1. This is not an 
unexpected result, because all subjects vere young, had normal renal function, and had 
the short t j f 2 ' s (mean 1.99 hours, first drav and 1.87 hours, second drav), that have 
been described in CF patients previously. 1 "3.5.15.16 since most patients vere dosed on 
an every eight hour schedule, it vas unlikely that their trough STC vould be elevated. 
A variety of problems occurred in the study vhich prevented data collection on 
some patients. We attempted to collect STC's on over 30 courses of therapy, but could only 
completely collect data for 16 patients. A discussion of some of these problems vill 
illustrate the difficulty in obtaining reliable STC's in the clinical setting, vhich is vhere 
pharmacokinetics ultimately must be applied. 
Occasionally the laboratory personnel drev peak STC's less than 30 minutes after 
the infusion of the dose. This resulted in peak concentrations that vere very high, 
probably because the drug vas still in its distributive phase. Early in the study, nurses 
sometimes forgot to record the time of doses, resulting in unusable data or delays in 
checking STC's. To prevent this, the nurse va3 contacted shortly before a dose vas due 
and reminded to record times. This vas necessary throughout the study. Occasionally, the 
phlebotomist forgot to vrite dovn the time of venipuncture; again, through constant 
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reminders, the implementation of the data collection sheet, and use of a central laboratory 
sign out sheet for blood draws, times of draws were finally consistently recorded. 
Sometimes patients would leave the ward and not be available for blood collection or dose 
administration. Some patients adamantly refused to have their blood drawn. More 
frequently, their reluctance caused the housestaff considerable distress, and thus the 
physicians refused to order STC's. Finally, STC's were occasionally obtained that were 
not believable (i.e. trough concentrations being greater than peak concentrations), 
possibly due to inadvertent mislabelling of patients' serum samples. 
In all of the above instances, either we could not obtain data or we did not use it in 
the reported results. In some of the above cases, without the interpretation and 
-e* 
intervention of a clinical pharmacist, unreliable STC's may have been used for making 
dosage change decisions by the physicians. Careful analysis of the way in which doses are 
given and venipunctures are done is necessary to prevent the use of unreliable laboratory 
values. 
An unexpected finding of this study was the lack of utility of both methods in 
predicting STC's. Because of the variability and lack of precision in predictive utility 
that was found, parameters that could account for changes observed in both Vd and k^, 
(maximum temperature and weight changes from the first STC to the second STC a few 
days later), were examined. These are listed in Table 5. When those patients whose STC's 
that were under predicted are compared to those that are over predicted, visual inspection 
of the data shows that a positive or negative change in either weight or temperature wa3 
not associated with either event. That is, positive and negative changes in weight and 
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temperature vere about equally distributed among patients vhose STC's vere 
under predicted and among those that vere over predicted. Additionally, serum creatinine, 
albumin, age, sex, or concurrent use of theophylli ne vere not associated vith either 
overprediction or underprediction of STC's. 
To determine if 8ny factor could be associated vith Vd, Vd values vere arranged in 
descendi ng order, both for the val ues based on the fi r3t set of STC's and the second set of 
STC's. The corresponding serum albumin concentration, veight change and temperature 
change vere plotted against these values for Vd. Visual inspection of the plots shoved no 
relationship betveen Vd and these three factors. When patients vhose Vd increased over 
time are compared to those vhose Vd decreased over time, and the presence of an i ncrease 
or decrease in temperature and veight are examined, there is no association betveen 
changes in Vd and positve or negative changes in temperature and veight (see Table 5). 
In addition, vhen patients vhose ke] increased over time are compared to those 
vhose ke l decreased over time, and the presence of an increase in temperature or a 
decrease i n temperature is exami ned, there is no relationshi p betveen the change i n 
temperature over time and the change in kgj. That is, positive and negative changes in 
temperature vere about equally distributed among patients vhose kej increased and among 
those vhose ke^ decreased. 
It vas not the objective of this study to examine the reasons for discrepancies 
betveen predicted and measured STC's, but the issue vill be addressed here. There are 
several possible explanations for vhy the STC's obtained may not have been reflective of 
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the true peek and trough. First, the dose mag not have been accurately measured by the 
pharmacy or completely infused by the nurse. Second, the dose may not have been given at 
the time recorded by the nurse. Third, perhaps the phlebotomists did not accurately 
record times of venipunctures. The samples may not have been promptly placed on ice 8nd 
centrifuged. Variability in the assay itself could account for some variability in the STC's, 
although not enough (only 3-4%) to account for the large variances from expected that 
were observed in STC's. Possibly, one-half hour after the infusion still constitutes the 
distributive phase for some patients,(resulting in elevated STC's), although most of the 
peak STC's vere drawn more than one-half hour after the infusion. Inactivation of 
tobramycin by the concur re ntly ad ministered a ntipseudomonal penicillin is a potential 
problem, although this is generally a clinically relevant problem only in patients with 
renal failure.22 In addition, the TDXR assay is probably capable of distinguishing 
between active and inactive tobramycin,23 and if any inactivation occurred, it should have 
been a constant from the first STC set to the second one, as dosing schedules for neither the 
penicillin nor the tobramycin were changed during the hospital stay. 
All of the above factors were possible reasons for the variations seen between 
predicted versus actual STC's. However, considerable effort was made to decrease the 
possibility of errors in all of the above factors. Another possible explanation, as to why 
measured STC's were not as predicted, is that there is a genuine change over time in the 
pharmacokinetic handling of tobramycin in CF patients over the course of their pulmonary 
exacerbation. Most subjects showed a stri ki ng change i n thei r Vd from about day 2 to day 
4 or 5 (SZ method: decrease i n mean Yd from 0.54 + 0.546 to 0.39 + 0.279 1 /kg). 
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Many patients had a change in their kg^ although it vas less striking than the change in Vd 
(increase in mean kel from 0.349 +.0.098 to 0.371 +.0.071 hr"1). Other authors 
have observed a change i n Yd for ami nogl ycosides i n CF patients over ti me,11 and vide 
interpatient variability in Yd.6 '7,9 Kelly states that 3ome patients demonstrated a 
decrease i n Vd vith i mprovement of thei r exacerbation.11 Most i nvestigators vho have 
studied ami nogl ycoside pharmacokinetics in CF have not calculated a second value for Vd 
from their second set of serum drug concentrations (SDC's)4"9 and thus it is not knovn 
vhether Vd changes occurred. Hovever, several authors reported that the SZ method 
vorked fairly veil in predicting SDC's,5-7 thus making it unlikely that changes in Vd 
occurred unless compensatory changes in ke l occurred. MacDonald et. al. studied 
pharmacokinetics of gentamicin in CF patients vho vere not in pulmonary exacerabation, 
and found no increase in Yd over non-CF populations (0.2051 /kg +.0.065 ) .1 2 They 
found that Yd did not correlate vith veight, percent body fat, severity of CF, age, or 
plasma clearance. They did find, hovever, that total plasma clearance did increase as 
severity of disease increased (as measured by decreases in forced expiratory volume in 
one second). These vere not intrapatient changes over time, but interpatient changes that 
vere plotted against one another. Unfortunately, it's not knovn if these relatively healthy 
CF patients had a change in their Vd over time. 
If there is a change in CF patients' pharmacokinetic parameters over the course of 
an exacerbation, vhat factors could account for this? A change i n veight could change the 
Vd,24 but we found no overall significant change in weight (mean decrease of 0.14 kg). 
An increase in temperature can decrease serum aminoglycoside concentrations,24 but we 
found an overall decrease in oral temperature of only 0.13 degrees Centigrade. A decrease 
in intravascular volume, due to Improvement of cor pulmonale during treatment, is a 
possible explanation, so that Vd could fluctuate with the degree of right sided heart 
failure 2 5 Although Vogelstein et. al. found an increased renal clearance of ami kacinin 
CF,8 other investigators have not been able to show an increased renal clearance.5,10 
There may bean incr eased penetration of aminoglycoside into sputum during inflammation 
of the pulmonary tissues; this penetration may decrease 8s antibiotic and chest 
physiotherapy continue.11 Sputum production may also decrease as the exacerbation 
lessens. Thus, perhaps nonrenal routes of elimination and nonvascular body 
compartments of distribution are more important early in the exacerbation than later. 
Protein binding may be different in CF patients; however. Levy et. al. found no difference 
in percent of drug bound between patients with CF and controls.10 They did not state if 
albumin concentrations were similar in both groups. Albumin concentration was just 
slightly less than normal in our patients at 3.8g/dl (+0.46). It is unlikely that albumin 
concentration would change over a short time, although perhaps other factors affecting 
protein binding might change over the course of an exacerbation. Another factor which 
could influence aminoglycoside pharmacokinetics is a change in red blood cell count over 
time.24 Finally, an increase in physical activity during the course of the hospitalization 
may play some as yet undetermined role on the STC. For instance, the effect of posture on 
plasma vol ume is often ignored when exami ni ng drug concentrations. Warren reports an 
increase in theophylline levels in upright subjects, possibly due to the 12-15 % 
reduction in plasma volume that occurs vith standing.26 
The reason for the change in tobramycin pharmacokinetics over time vhich ve 
observed is not knovn. If tobramycin pharmacokinetics change over a period of 4-5 days, 
do they change significantly upon the patients's subsequent hospital admission one to six 
months later? The one patient vhom ve studied on a second hospitalization had completely 
different pharmacokinetic para meters deter mined during the second ad mission. DoCF 
patients' pharmacokinetic parameters change continually throughout the course of the 
hospitalization? Should ve feel confident that checki ng one set of peak and trough val ues 
per 8dmis3ion (as has been done frequently in the past) can adequately describe and 
predict pharmacokinetic values for a given patient for their entire hospitalization? One 
set of STC's is probably not adequate to define a CF patient's pharmacokinetic profile. Is it 
necessary and cost-effective to frequently check peak and trough values to ensure adequate 
tobramycin concentrations at all times? This question could only be conclusively 
ansvered by a comparative trial of constantly individualized therapy versus high dose, 
only partly individually dosed aminoglycoside therapy. 
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CONCLUSIONS 
We found no statistically significant difference between the SZ method and the SP 
method in their utility at predicting STC's in CF patients. The SP method is preferable, 
because of its ease of use, if one can be assured of accurately collected blood samples. The 
utility of either method, however, for any given patient with CF, is questionable, given the 
possible physiologic changes that occur in CF patients during a pulmonary exacerbation of 
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TABLE 1 
PREDICTION ERROR  1 (PE) 
THIRTY MINUTE POST-INFUSION SERUM TOBRAMYCIN CONCENTRATIONS 
patient Predicted Predicted Measured SZ_(PE)_ sp_(pe: 
number SIC2<SZ)_5 STC (SP)* STC 
1 3.3 3.5 13.3 -10.0 -9.8 
2 7.7 7.8 9.4 -1.7 -1.6 
3 8.2 8.1 8.8 -0.6 -0.7 
4 8.6 8.5 8.9 -0.3 -0.4 
5 13.2 13.2 9.3 3.9 3.9 
6 8.1 8.3 12.0 -3.9 -3.7 
7 7.5 7.4 12.8 -5.3 -5.4 
8 8.5 7.9 9.9 -1.4 -2.0 
9 2.9 3.0 13.4 -10.5 -10.4 
10 8.3 8.6 5.4 2.9 3.2 
11 8.8 8.9 11.7 -2.9 -2.8 
12 6.8 6.9 2.1 4.7 4.8 
13 9.9 9.6 5.5 4.4 4.1 
14 8.5 8.7 5.2 3.3 3.5 
15 7.5 7.5 8.0 -0.5 -0.5 
16 8.9 8.9 9.3 -0.4 -0.4 
Mean -1.14 -1.13 
S.D. ±4.64 ±4.60 
1 predicted minus measured serum tobramycin concentrations in mg/1 
2 STC = serum tobramycin concentration in mg/1 
3 SZ = Savchuk-Zaske method 
4 SP = Simplified Pharmacokinetics method 
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TABLE 2 
PREDICTION ERROR1 (PE) 
ONE MINUTE PRE-INFUSION SERUM TOBRAMYCIN CONCENTRATIONS 
patient Predicted Predicted Measured SZ(PE) SP(PE) 
number STC? (SZ)3 STC (SP)4 STC 
1 0.8 1.0 1.7 -0.9 -0.7 
2 1.6 1.7 1.3 0.3 0.4 
3 0.6 0.6 0.5 0.1 0.1 
4 0.4 0.7 0.4 0.0 0.3 
5 1.1 1.1 0.7 0.4 0.4 
6 - 1.8 1.9 0.8 1.0 1.1 
7 1.5 1.4 0.9 0.6 0.5 
8 0.4 0.4 0.7 -0.3 -0.3 
9 0.4 0.5 1.4 -1.0 -0.9 
10 0.6 0.7 0.5 0.1 0.5 
11 0.4 0.4 0.6 -0.2 -0.2 
12 0.8 0.8 0.4 0.4 0.4 
13 0.5 0.5 0.5 0.0 0.0 
14 0.5 0.5 0.3 0.2 0.2 
15 0.8 0.8 0.9 -0.1 -0.1 
16 1.0 1.1 1.0 0.0 0.1 
Mean 0.04 0.09 
S.D. ±0.50 ±0.45 
1 predicted minus measured serum tobramycin concentrations in mg/1 
2 STC = serum tobramycin concentrtion in mg/1 
3 SZ = Sawchuk-Zaske method 
4 SP = Simplified Pharmacokinetics method 
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TABLE 3 






















Vdj* Vd2* Vdj * Vd 2
# 
2.26 0.47 2.69 0.59 
0.39 0.30 0.45 0.37 
0.38 0.34 0.51 0.46 
0.35 0.35 0.48 0.47 
0.16 0.22 0.20 0.29 
0.59 0.30 0.68 0.41 
0.69 0.30 0.81 0.39 
0.30 0.24 0.42 0.34 
1.40 0.26 1.68 0.35 
0.25 0.40 0.32 0.51 
0.23 0.19 0.31 0.24 
0.39 1.40 0.47 1.70 
0.17 0.32 0.26 0.46 
0.24 0.39 0.32 0.53 
0.45 0.43 0.56 0.53 
0.37 0.35 0.47 0.45 
0.539 0.391 0.664 0.506 
±0.546 ±0.279 ±0.641 ±0.332 
*Vdj is calculated based on the first set of STC's 
*Vd2 is calculated based on the second set of STC's 
TABLE 4 
ELIMINATION RATE CONSTANTS (ke l) in hours" 1 
patient ^ 2 * 
number 
1 0.28 0.42 
2 0.22 0.29 
3 0.39 0.41 
4 043 0.43 
5 0.36 0.3b 
6 0.22 0 40 
7 0.23 0.37 
8 0.43 0.40 
9 0.27 0.35 
10 0.37 0.31 
11 0.44 0.43 
12 0.30 0.22 
13 0.58 0.52 
14 0.42 0.39 
15 0.32 0.31 
16 032 0,32 
Mean 0.349 0.371 
S.D. ±0.098 ±0.071 
•measured from fi rst set of serum tobramyci n concentrations 
'measured from second set of serum tobramycin concentrations 
TABLE 5 
PREDICTION ERROR FOR PEAK SERUM TOBRAMYCIN CONCENTRATIONS AND CHANGES IN YOLUME OF 
DISTRIBUTION (Yd), ELIMINATION RATE CONSTANT (kel), WEIGHT, AND MAXIMUM TEMPERATURE 
Pt no. PE1 PE2 AVd? iVd4 A kel5 AVt6 Atemp 
1 -10.0 -9.7 -1.79 -2.10 0.14 -0.5 0.4 
2 -1.7 -1.6 -0.09 -0.08 0.07 -2.7 -0.1 
3 -0.6 -0.7 -0.04 -0.05 0.02 0.1 -1.0 
4 -0.3 -0.4 0.0 -0.01 0.0 -0.5 -0.8 
5 3.9 3.9 0.06 -0.09 0.0 0.0 0.2 
6 -3.9 -3.7 -0.29 -0.27 0.18 -0.4 -0.5 
? -5.3 -5.4 -0.39 -0.42 0.14 1.0 -0.7 
8 -1.4 -2.0 -0.06 -0.08 -0.03 0.0 -0.07 
9 -10.5 -10.4 -1.14 -1.33 0.08 0.1 0.3 
10 2.9 3.2 0.15 0.19 -0.06 1.2 -0.1 
11 -2.9 -2.8 -0.04 -0.07 -0.01 -0.7 -0.8 
12 4.7 4.8 1.01 1.23 -0.08 -0.1 1.4 
13 4.4 4.1 0.15 0.20 -0.06 0.03 1.0 
14 3.3 3.5 0.15 0.27 -0.03 -0.5 0.8 
15 -0.5 -0.5 -0.02 -0.03 -0.01 0.0 -0.5 
16 -0.4 -0.4 -0.02 -0.02 0.0 0.7 -0.4 
Mean -1.14 -1.13 -0.148 -0.166 0.022 -0.14 -0.13 
S.D. ±4.64 ±4.60 ±0.605 ±0.715 ±0.078 ±0.87 ±0.71 
1 PE = prediction error in mg/1 for peak serum tobramycin concentrations (STC's) for 
Sawchuk-Zaske (SZ) method 
2 PE = prediction error in mg/1 for peak STC's for Simplified Pharmacokinetics (SP) method 
3 a Yd = Yd (in 1/kg) calculated based on second set of STC's minus Vd calculated based on first set of 
STC's using the SZ method* 
4 AVd = Vd (in 1/kg) calculated based on second set of STC's minus Yd calculated based on first set of 
STC's using the SP method* 
5 Akel = kel (in hours -1) calculated based on second set of STC's minus kel calculated based on 
first set of STC's (same for both methods)* 
6 avt = veight (in kg) on day of second set of STC's minus the veight on day of first set of STC's* 
? Atemp = maximum temperature in degrees Centigrade (oral) on day of second 3et of STC's minus 
maximum temperature on day of first set of STC's* 
•second set of STC's vere obtained a mean of 68 hours after the first set of STC's 
32 
REFERENCES 
1. Noone P, Parsons TMC,Pattison JR, Slack RB, Garfield-Da vies D, Hughes K. Experience 
in monitorinq gentamicin therapy during treatment of serious gram-neqative sepsis. Br 
Med J 1974;1:477-81. 
2. Moore RD, Smith CR, Leitman PS. Association of aminoglycoside plasma levels with 
therapeutic outcome in gram-negative pneumonia. Am J Med 1984;77:657-62. 
3. Fraser GL, Grimes GR, Volenti AJ. Applied pharmacokinetics in acute exacerbations of 
Pseudomonas aeruginose pneumonia in cystic fibrosis. J Pediatr 1982; 101: 792-3. 
4. Hsu M, Aguila HA, Schmidt YL, Mun2enberger PJ, Kauffman RE, Polg8r G. 
Individualization of tobramycin dosage in patients with cystic fibrosis. Pediatr Infect Dis 
1984; 3: 526-9. 
5. Kearns.GL, Hilman BC, Wilson JT. Dosing implications of altered gentamicin disposition 
in patients with cystic fibrosis J Pediatr 1982; 100:312-8. 
6. Bauer LA, Piecoro JJ, Wilson HD, Blouin RA. Gentamicin and tobramycin 
pharmacokinetics in patients with cystic fibrosis. Clin Pharm 1983;2:262-4. 
7. Kelly HG, Menendez R. Fan L, Murphu S. Pharmacokinetics of tobramycin in cystic 
fibrosis. J Pediatr 1982; 100:319-21. 
8. Yogelstein B, Kowarski AA, Lietman PS. The pharmacokinetics of amikacin in children. 
J Pediatr 1979;94: 163-4. 
9. Finkelstein E, Hall K. Aminoglycoside clearance in patients with cystic fibrosis 
(letter). J Pediatr 1979;94:163-4. 
10. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of 
tobramycin in patients with cqstic fibrosis: a prospectve controlled study, J Pediatr 
1 984;105: 117-24. 
11. Kelly HW, Lovato C. Antibiotic use in cystic fibrosis. Drug Intell Clin Pharm 
1984;18:772-83. 
12. Mac Donald NE, Anas NG, Peterson RG, Schwartz RH, Brooks JG, Powell KR. Renal 
clearance of gentamicin in cystic fibrosis. J Pediatr 1983; 103: 985-90. 
13.Sawchuk RJ, Z8Ske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for 
gentamicin dosing vith the use of individual patient parameters. Clin Pharmacol Ther 
1977;21:362-9. 
14. Savchuk RJ, Zaske DE. Pharmacokinetics of dosing regimes vhich utilize multiple 
intravenous infusions: gentamicinin burn patients. J Pharmacol net Biopharm 
1976;4:183-95. 
15. De Yito JM, Crass RE. Calculating aminoglycoside kinetic parameters. Drug Intel! Clin 
Pharm 1984;18: 645-6. 
16. Associated Regional and University Pathologists information, Salt Lake City, UT. 
17. Matzke GR, Lucarotti RL, Shapiro HS. Controlled comparison of gentamicin and 
tobramycin nephrotoxicity. Am J Nephrol 1983;3:11-7. 
18. Dahlgren JG, Anderson ET, Hevitt WL. Gentamicin blood levels: a guide to 
nephrotoxicity Antimicrob Agents Chemother 1975;8: 58-62. 
19. Sheiner LB, Beal SL. Some suggestions for measuring predictive 
performance. J Pharmacokin Biopharm 1981 ;9:503-12. 
20. Zaske DE, Cipolle RJ, Rotschafer X , Solem LD, Mosier NR, Strate RG. Gentamicin 
pharmacokinetics in 1640 patients: method for control of serum concentrations. 
Antimicrob Agents Chemother 1982;21:407-11. 
21. Evans WE, FelmanS, Barker LF, Ossi M,Chaudhary S. Use of gentamicin serum levels 
to individualize therapy in children. J Pediatr 1978;93: 133-7. 
22. Riff LJ, Jackson GG. Laboratory and clincial conditions for gentamicin inactivation by 
carbenicillin. Arch Int Med 1972,130: 887-91. 
23. Dal mady-Israel C, Green PJ, Sloskey GE, Vlasses PH. Ticarcillin and assay of 
tobramycin. Ann Int Med 1984;100: 460-1. 
24. Schentag JJ. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied 
Pharrrtcokinetic. San Francisco: Applied Therapeutics, Inc.,1980: 227-8. 
25. Knapp CA, Hess DA. Aminoglycoside pharmacokinetics in cystic fibrosis. Clin 
Pharmacokin Newsletter 1984,1:1-2. 
26. Warren J. Theophylline concentrations and posture. Lancet 1983;2:850. 
VITA 
Mary Violet Relling 
Born: February 28, 1960 
Place of birth: Phoenix, Arizona 
April 1985 
EDUCATION 
July 1983 to 
June 1985 
July 1977 to 
May 1962 
College of Pharmacu. Universitu of Utah. Salt Lake Citu. UT 
Doctor of Pharmacy, August, 1985 
College of Pharmacu. Universitu of Arizona. Tucson, AZ 
Bachelor of Science, Pharmacy , May, 1982 
PROFESSIONAL EXPERIENCE and TRAIN!NG 
July 1983 to Universitu Hospital. Universitu of Utah. Salt Lake Citu. UT 
June 1985 Certificate of Residency in Clinical Pharmacy Practice 
July 1983 to ** Veterans Administration Medical Center. Salt Lake Citu. UT 
June 1985 Pharmacist 
May 1982 to Veterans Administration Medical Center. Tucson. AZ 
June 1983 Pharmacist 
January 1982 to 
May 1982 
December 1979 to 
May 1982 
October 1981 to 
May 1982 
May 1981 to 
August 1981 
June 1980 to 
April 1981 
May 1979 to 
October 1979 
Kino Communitu Hospital and Veterans Administration Medical Center 
Tucson. AZ 
Pharmacy Extern 
Universitu Hospital. Arizona Health Sciences Center. Tuscon. AZ 
Pharmacy intern 
Arizona Poison Control and Drug Information Center. Tucson. AZ 
Volunteer 
Universitu Hospital. Arizona Health Sciences Center. Tucson, AZ 
Research Assistant 
SanXavier Indian Health Clinic. Public Health Service. Tucson, AZ 
Pharmacy Volunteer 
The Prescription Shop. Tucson, AZ 
Pharmacy Intern 
35 
AWARDS AND HONORS 
1983-85 Grace P. Swinyard Scholarship Recipient 
1982 Graduated vith High Distinction, University of Arizona 
1982 Bristol Avard Reci pient 
1981-82 Andrew P. Martin Scholarship Recipient 
1980 Rho Chi Society Member, University of Arizona 
1980-81 University Class Scholarship Honors, University of Arizona 
1979-80 Outstanding Scholastic Acheivement, College of Pharmacy, University of 
Arizona 
1979- 80 ^ Outstandi ng Service Avard, Student American Pharmaceutical Association, 
Tucson, AZ 
